Figure 15.

Reducing biomarker abnormality through increased clearance. Increasing the clearance ${\tilde{k}}_1$ delays and reduces the accumulation of misfolded tau protein $\tilde{p}$ and with it the biomarker abnormality $\tilde{\mathcal{P}}$. Depending on the clearance rate ${\tilde{k}}_1$, the misfolded protein concentration of the Heterodimer model can converge towards intermediate states with a reduced biomarker abnormality of $\tilde{\mathcal{P}}<100\text{\%}$. (Online version in colour.)